RPL36AP14

Across TCGA pan-cancer cohorts, RPL36AP14 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated RPL36AP14 data layer.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher RPL36AP14 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL36AP14 expression acts as an unfavorable survival marker.

LAML, STAD, and KIRC are the cancer types where RPL36AP14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Tertile	All	0.375	0.627	<.001	54	view →
STAD	DFS	Tertile	IV	0.097	0.412	.008	17	view →
KIRC	DFS	Tertile	II,III,IV	0.546	0.726	.029	9	view →
HNSC	DFS	Tertile	II,III,IV	0.513	0.705	.027	9	view →
LGG	DFS	Tertile	All	0.156	0.434	.043	6	view →
SARC	OS	Tertile	All	0.521	0.752	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPL36AP14–LAML (DFS)

Open the LAML breakdown →